New formulation of oxycontin complaints.asp

Oct 24, 2019 · The FDA approves a new formulation of OxyContin that is more difficult to crush, chew and dissolve. 2016. The CDC issues more conservative guidelines for prescribing opioids for chronic pain. It is estimated that Purdue has made more than $36 billion in revenue from OxyContin. 2019

April 7, 2010 — The US Food and Drug Administration (FDA) has approved a new formulation of controlled-release oxycodone HCl (Oxyontin, Purdue Pharmaceuticals) designed to discourage misuse and abuse of the medication, which is indicated for the management of moderate to severe pain when a continuous, around-the-clock analgesic is required for an ...

OxyContin Tablets are a controlled-release oral formulation of oxycodone hydrochloride indicated for the management of moderate to severe pain when a continuous, around-the-clock analgesic is needed for an extended period of time. OxyContin Tablets are NOT intended for use as a prn analgesic. I have sincere hope that the new formulation of OxyContin will remain difficult, if not impossible, to break down for illicit use, and yet still remain effective for legitimate patients. Time will tell, as this is truly a unique opportunity to compare “apples to apples” over the next several months and years.

“Although this new formulation of OxyContin may provide only an incremental advantage over the current version of the drug, it is still a step in the right direction,” said Bob Rappaport, M.D., director of the Division of Anesthesia and Analgesia Products in the FDA’s Center for Drug Evaluation and Research.